OKYO Pharma Ltd. has released its annual report for the fiscal year ending March 31, 2025. The company reported that it has not generated any revenue from product sales to date and does not anticipate generating such revenue in the near future. This is due to the ongoing development efforts for their product candidates, which have not yet resulted in regulatory approval. The report outlines that OKYO Pharma Ltd. continues to focus on research and development, which is reflected in their operating expenses. The company has not provided specific figures for net income or profit/loss, as their efforts remain in the developmental stage with no revenue generation from product sales. There is no specific guidance or outlook provided in the report regarding future earnings per share or revenue expectations. The company's strategy remains centered on advancing their product candidates through development and eventual regulatory approval to achieve future revenue generation.